October 2026
Quercetin COVID-19 outcomes
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Di Pierro (RCT)86%0.14 · 0.01–2.72death0/763/76
Di Pierro (RCT)94%0.06 · 0.00–1.00ICU0/768/76
Di Pierro (RCT)68%0.32 · 0.14–0.70hosp.7/7622/76
Khan (RCT)33%0.67 · 0.37–1.19no recov.10/2515/25CT1
Khan (RCT)39%0.61 · 0.43–0.87no recov.25 (n)25 (n)CT1
Khan (RCT)50%0.50 · 0.30–0.84viral+10/2520/25CT1
Di Pierro (RCT)67%0.33 · 0.01–7.99death0/501/50
Di Pierro (RCT)67%0.33 · 0.01–7.99ICU0/501/50
Di Pierro (RCT)67%0.33 · 0.01–7.99hosp.0/501/50
Di Pierro (RCT)37%0.63 · 0.46–0.88no recov.24/5038/50
Di Pierro (RCT)58%0.42 · 0.27–0.65viral+16/5038/50
Di Pierro (RCT)−50%1.50 · 0.26–8.60viral+3/502/50
Di Pierro (RCT)67%0.33 · 0.01–7.99viral+0/501/50
Din Ujjan (RCT)29%0.71 · 0.50–1.03no recov.15/2521/25CT1
Din Ujjan (RCT)71%0.29 · 0.14–0.59no recov.6/2521/25CT1
Din Ujjan (RCT)77%0.23 · 0.07–0.71no recov.3/2513/25CT1
Din Ujjan (RCT)86%0.14 · 0.01–2.63no recov.0/253/25CT1
Din Ujjan (RCT)91%0.09 · 0.01–1.56viral+0/255/25CT1
Din Ujjan (RCT)74%0.26 · 0.12–0.59viral+5/2519/25CT1
Zupanets (RCT)29%0.71 · 0.32–1.58no recov.9/9913/101
Zupanets (RCT)18%0.82 · 0.68–0.98recov. time99 (n)101 (n)
Shohan (RCT)86%0.14 · 0.01–2.65death0/303/30
Shohan (RCT)40%0.60 · 0.16–2.29ICU3/305/30
Shohan (RCT)32%0.68 · 0.47–0.98recov. time30 (n)30 (n)
Gérain (RCT)67%0.33 · 0.01–7.70death0/251/24CT1
Gérain (RCT)91%0.09 · 0.01–1.53death/ICU0/255/24CT1
Gérain (RCT)89%0.11 · 0.01–1.92ventilation0/254/24CT1
Gérain (RCT)89%0.11 · 0.01–1.92ICU0/254/24CT1
Gérain (RCT)73%0.27 · 0.06–1.19no disch.2/257/24CT1
Gérain (RCT)59%0.41 · 0.19–0.89no disch.6/2514/24CT1
Gérain (RCT)38%0.62 · 0.44–0.88hosp. time25 (n)24 (n)CT1
Gérain (RCT)50%0.50 · 0.26–0.97no recov.22 (n)24 (n)CT1
Tylishchak (RCT)40%0.60 · 0.16–2.29no recov.3/305/30
Tylishchak (RCT)15%0.85 · 0.81–0.89hosp. time30 (n)30 (n)
Rondanelli (DB RCT)93%0.07 · 0.01–0.91symp. case1/604/60
00.511.52+